NanoViricides Inc Cash Flow Conversion Efficiency
NanoViricides Inc cash flow conversion efficiency. Based on the latest financial reports, NanoViricides Inc (NNVC) has a cash flow conversion efficiency ratio of -0.222x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.59 Million) by net assets ($7.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of NanoViricides Inc (2006–2025)
Cash flow conversion efficiency of NanoViricides Inc from 2006 to 2025. This chart illustrates how NanoViricides Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest NanoViricides Inc stock price today for real-time trading data and today's change.
NanoViricides Inc Cash Flow Conversion Ratio Explained
NanoViricides Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NanoViricides Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NanoViricides Inc ranked by their cash flow conversion efficiency. Also see NNVC stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Environmental Clean Technologies Ltd
AU:ECT
|
-0.043x |
|
Sufrin Holdings Ltd
TA:SFRN
|
N/A |
|
Trek Metals Ltd
AU:TKM
|
-0.027x |
|
Borneo Oil Bhd
KLSE:7036
|
-0.019x |
|
Tah Tong Textile Co Ltd
TW:1441
|
0.014x |
|
NamSys Inc
V:CTZ
|
0.102x |
|
MiniLuxe Holding Corp
V:MNLX
|
0.103x |
|
Japan Gold Corp
V:JG
|
-0.051x |
Annual Cash Flow Conversion Efficiency for NanoViricides Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of NanoViricides Inc from 2006 to 2025. Review NanoViricides Inc financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $7.52 Million | $-8.48 Million | -1.128x | -104.73% |
| 2024-06-30 | $11.46 Million | $-6.32 Million | -0.551x | -44.43% |
| 2023-06-30 | $14.87 Million | $-5.67 Million | -0.381x | -49.44% |
| 2022-06-30 | $23.08 Million | $-5.89 Million | -0.255x | +7.06% |
| 2021-06-30 | $29.91 Million | $-8.21 Million | -0.275x | +10.36% |
| 2020-06-30 | $21.76 Million | $-6.67 Million | -0.306x | +52.26% |
| 2019-06-30 | $10.60 Million | $-6.80 Million | -0.642x | -45.78% |
| 2018-06-30 | $17.66 Million | $-7.78 Million | -0.440x | -13.27% |
| 2017-06-30 | $20.32 Million | $-7.90 Million | -0.389x | -31.16% |
| 2016-06-30 | $23.05 Million | $-6.83 Million | -0.296x | -51.60% |
| 2015-06-30 | $31.79 Million | $-6.21 Million | -0.195x | +11.73% |
| 2014-06-30 | $28.60 Million | $-6.33 Million | -0.221x | +69.41% |
| 2013-06-30 | $8.01 Million | $-5.80 Million | -0.724x | -137.68% |
| 2012-06-30 | $13.85 Million | $-4.22 Million | -0.305x | +31.28% |
| 2011-06-30 | $10.17 Million | $-4.51 Million | -0.443x | -41.10% |
| 2010-06-30 | $6.52 Million | $-2.05 Million | -0.314x | +70.89% |
| 2009-06-30 | $2.49 Million | $-2.68 Million | -1.079x | +81.22% |
| 2008-06-30 | $443.74K | $-2.55 Million | -5.747x | -23.25% |
| 2007-06-30 | $500.34K | $-2.33 Million | -4.663x | -216.69% |
| 2006-06-30 | $1.24 Million | $-1.82 Million | -1.472x | -- |
About NanoViricides Inc
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product for… Read more